The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2

Cancer Research

Volumn 65, Issue 21, 2005, Pages 9991-9998

  Guo, Z Sheng ^a   Naik, Arpana ^c   O'Malley, Mark E ^a   Popovic, Petar ^a   Demarco, Richard ^a,b   Hu, Yun ^c   Yin, Xiaoyu ^a,e   Yang, Shuting ^a   Zeh, Herbert J ^a   Moss, Bernard ^d   Lotze, Michael T ^a,b   Bartlett, David L ^a,c,f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e SUN YAT SEN UNIVERSITY   (China)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; HIGH MOBILITY GROUP B1 PROTEIN; ONCOLYTIC VIRUS; PROTEIN P53; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG SELECTIVITY; FEMALE; FLOW CYTOMETRY; GENE; GENE DELETION; HOST RANGE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VITRO STUDY; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SPI 1 GENE; SPI 2 GENE; SUPERNATANT; SURVIVAL; TUMOR MODEL; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS PATHOGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

ANIMALS; APOPTOSIS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; FEMALE; GENE DELETION; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 27544491235     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1630     Document Type: Article

References (52)

1. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2: 938-50.
2. Mastrangelo MJ, Lattime EC. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther 2002;9: 1013-21.
3. Vile R, Ando D, Kim D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002;9: 1062-7.
4. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002;9:1001-12.
5. Stanziale SF, Fong Y. Novel approaches to cancer therapy using oncolytic viruses. Curr Mol Med 2003;3: 61-71.
6. Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 2004;4:901-17.
7. Thorne SH, Kirn DH. Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus. Expert Opin Biol Ther 2004;4:1307-21.
8. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 2005; 11:180-95.
9. Bartlett DL. Vaccinia virus. In: Hernáiz Driever P, Rabkin SD, editors. Replication-competent viruses for cancer therapy. Monogr Virol. Vol. 22. Basel (Switzerland): Karger; 2001. p. 130-59.
10. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7.
11. Hay S, Kannourakis G. A time to kill: viral manipulation of the cell death program. J Gen Virol 2002;83: 1547-64.
12. Boya P, Pauleau AL, Poncet D, Gonzalez-Polo RA, Zamzami N, Kroemer G. Viral proteins targeting mitochondria: controlling cell death. Biochim Biophys Acta 2004;1659:178-89.
13. Elkert PG, Silke J, Vaux DL. Caspase inhibitors. Cell Death Diff 1999;6:1081-6.
14. Silver GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. J Biol Chem 2001;276: 33293-6.
15. Everett H, McFadden G. Poxviruses and apoptosis: a time to die. Curr Opin Microbiol 2002;5:395-402.
16. Kotwal GJ, Moss B. Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. J Virol 1989;63:600-6.
17. Zhou J, Sun XY, Fernando GJ, Frazer IH. The vaccinia virus K2L gene encodes a serine protease inhibitor which inhibits cell-cell fusion. Virology 1992;189:678-86.
18. Ali AN, Turner PC, Brooks MA, Moyer RW. The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology 1994; 202:305-14.
19. Brooks MA, Ali AN, Turner PC, Moyer RW. A rabbitpox virus serpin gene controls host range by inhibiting apoptosis in restrictive cells. J Virol 1995;69: 7688-98.
20. Moon KB, Turner PC, Moyer RW. SPI-1-dependent host range of rabbitpox virus and complex formation with cathepsin G is associated with serpin motifs. J Virol 1999;73:8999-9010.
21. Wasilenko ST, Meyers AF, Helm KV, Barry M. Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore. J Virol 2001;75:11437-48.
22. Dobbelstein M, Shenk T. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol 1996;70:6479-85.
23. Macen JL, Gamer RS, Musy PY, et al. Differential inhibition of the Fas- and granule-mediated cytolysis pathways by the orthopoxvirus cytokine response modifier A/SPI-2 and SPI-1 protein. Proc Natl Acad Sci U S A 1996;93:9108-13.
24. Kettle S, Alcami A, Khanna A, Ehret R, Jassoy C, Smith GL. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J Gen Virol 1997;78:677-85.
25. Shisler JL, Isaacs SN, Moss B. Vaccinia virus serpin-1 deletion mutant exhibits a host range defect characterized by low levels of intermediate and late mRNAs. Virology 1999;262:298-311.
26. Law KM, Smith GL. A vaccinia serine protease inhibitor which prevents virus-induced cell-fusion. J Gen Virol 1992;73:549-57.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
28. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2:277-88.
29. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumor cells. Nat Rev Cancer 2004;4: 592-603.
30. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004;16:663-9.
31. Roper RL, Moss B. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J Virol 1999;73:1108-17.
32. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000;7:1217-23.
33. Gnant MFX, Puhlmann M, Alexander HR, Jr., Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor specific gene expression and prolongation of survival in mice. Cancer Res 1999;59:3396-404.
34. Mahalingam S, Karupiah G. Modulation of chemokines by poxvirus infections. Curr Opin Immunol 2000; 12:409-12.
35. Ramsey-Ewing A, Moss B. Apoptosis induced by a postbinding step of vaccinia virus entry into Chinese hamster ovary cells. Virology 1998;242:138-49.
36. Li M, Beg AA. Induction of necrotic-like cell death by tumor necrosis factor α and caspase inhibitors: novel mechanism for killing virus-infected cells. J Virol 2000; 74:7470-7.
37. Humlova Z, Vokurka M, Esteban M, Melkova Z. Vaccinia virus induces apoptosis of infected macrophages. J Gen Virol 2002;83:2821-32.
38. Scaffidi P, Misteli T, Blanchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
39. Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:1-6.
40. Smith GL, Law M. The exit of vaccinia virus from infected cells. Virus Res 2004;106:189-97.
41. Wasilenko ST, Stewart TL, Meyers AF, Barry M. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc Natl Acad Sci U S A 2003;100:14345-50.
42. Stewart TL, Wasilenko ST, Barry M. Vaccinia virus F1L protein is a tail-anchored protein that functions at the mitochondria to inhibit apoptosis. J Virol 2005;79: 1084-98.
43. Garcia MA, Guerra S, Gil J, Jimenez V, Esteban M. Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 2002; 21:8379-87.
44. Zeh HJ, Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 2005;28:1-9.
45. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4: 641-8.
46. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
47. Chu JJH, Ng ML. The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J Gen Virol 2003;84:3305-14.
48. Joseph T, Cepica A, Brown L, Ikede BO, Kibenge FSB. Mechanism of cell death during infectious salmon anemia virus infection is cell type-specific. J Gen Virol 2004;85:3027-36.
49. Kettle S, Blake NW, Law KM, Smith GL. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 1995;206:136-47.
50. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 1996;93:11341-8.
51. Essajee S, Kaufmann HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4: 575-88.
52. Legrand FA, Verardi PH, Jones LA, Chan KS, Peng Y, Yilma TD. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J Virol 2004;78: 2770-9.